Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

Stocks closed higher on Tuesday as the Nasdaq Composite finished the day higher for the year even as uncertainty over global ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.63M to 6.10M. This put 21.56% of the company's publicly available shares short.

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

North Branch Land Trust is inviting nature lovers, conservationists and families to attend their Paddle and Pour event at 11 ...

Duck Dynasty's' Phil Robertson, who is suffering with Alzheimer's disease, harvested his first ducks as an 11-year-old boy ...

A breathtaking 30-kilometer ride offers constant views of breathtaking landscapes Nestled in the western foothills of Taiwan’s Central Range, Sun Moon Lake is a world unto itself, renowned for ...

On Monday, Wolfe Research analyst Andy Chen revised the rating for Moonlake Immunotherapeutics (NASDAQ:MLTX) upward, moving from Peerperform to Outperform. Accompanying this upgrade is a new price ...